A Phase II Study of Systemic Consolidation Therapy With Paclitaxel Plus Carboplatin Following Radical Hysterectomy and Adjuvant Chemoradiation for High Risk Early Stage Cervical Cancer

Inclusion Criteria:

- patients who underwent radical hysterectomy for cervical cancer stage IB-IIA

- Patients who had at least one of the following risk factors in pathologic results;
lymph node metastasis, positive residual resection margin, parametrial invasion

- above 20 years

- GOG performance status 0-2

- Informed consent

- Platelet>100K, Hb> 10.0 g/dl, ANC>1500/mm3, Cr <1.25*upper normal limit,
bilirubin<1.5mg/dl, AST & ALT<*3 upper normal limit

- Expected life > 6 months

Exclusion Criteria:

- Peripheral neurotoxicity > NCI grade 2

- Sever infection

- Previous history with chemotherapy or radiation therapy

- Pleural effusion, pericardial effusion, and ascites which could cause dyspnea > NCI
grade 2

- Paraaortic lymph node metastasis

- Allergy with platinum

- Previous history of atrial or ventricular arrhythmia or congestive heart failure

- Uncontrolled infection, diabetes mellitus, hypertension, ischemic heart disease,
myocardiac infarct within 6 months

- Severe disease such as acute or chronic renal failure and acute cerebral infarct,
cerebral hemorrhage, recurrent hepatitis, liver cirrhosis, unknown fever above 39
degrees centigrade